US 12,247,977 B2
Nasopharyngeal protein biomarkers of acute respiratory virus infection and methods of using same
Thomas W. Burke, Durham, NC (US); Ricardo Henao Giraldo, Durham, NC (US); Erik Soderblom, Raleigh, NC (US); Joseph Lucas, Chapel Hill, NC (US); Christopher W. Woods, Durham, NC (US); and Geoffrey S. Ginsburg, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Appl. No. 16/483,113
Filed by Duke University, Durham, NC (US)
PCT Filed Feb. 2, 2018, PCT No. PCT/US2018/016611
§ 371(c)(1), (2) Date Aug. 2, 2019,
PCT Pub. No. WO2018/144834, PCT Pub. Date Aug. 9, 2018.
Claims priority of provisional application 62/454,260, filed on Feb. 3, 2017.
Prior Publication US 2019/0376969 A1, Dec. 12, 2019
Int. Cl. G01N 33/569 (2006.01); C07K 14/005 (2006.01); G01N 33/577 (2006.01)
CPC G01N 33/56983 (2013.01) [C07K 14/005 (2013.01); G01N 33/577 (2013.01); G01N 2333/005 (2013.01); G01N 2469/10 (2013.01)] 20 Claims
 
1. A method of treating a subject having an acute respiratory viral (ARV) illness, wherein the ARV illness is caused by an influenza pathogen, said method comprising:
(1) determining an etiology of the illness comprising:
(a) obtaining a biological sample from the nasopharyngeal space or endotracheal site of the subject;
(b) measuring on a platform expression levels of pre-determined set of proteins and/or peptides for the platform in said biological sample, wherein the pre-determined set of proteins and/or peptides comprises form 9 to 26 proteins and/or component peptides/epitopes listed in Table 2/2A or Table S4 , and comprises A1AG1, TIG1, ANXA2, LCN15, ANGT, CFAB, TBA1B, CAYP1 and STAT, and wherein the measuring comprises detection and quantification of the proteins and/or component peptides/epitopes;
(c) normalizing the expression levels to generate normalized expression values;
(d) entering the normalized expression values into one or more acute respiratory virus (ARV) illness classifiers, said classifier(s) comprising pre-defined weighting values for each of the proteins and/or peptides for the platform; and
(e) calculating an etiology probability for the ARV illness based upon said normalized expression values and said classifier(s),
wherein said subject is determined to have the ARV illness; and
(2) administering to the subject an appropriate treatment regimen,
wherein said appropriate treatment regimen comprises an antiviral therapy.